Study | Sample type | Analytical platform | Un-saturated fatty acid | Saturated fatty acid | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Palmitoleic acid | Cervonic acid | Linoleic acid | Oleic acid | Linolenic acid | Vaccenic acid | Gondoic acid | Arachidonic acid | Myristic acid | Enanthic acid | Margaric acid | Caprylic acid | |||
GC | ||||||||||||||
Song (2011)59 | Tissue | GC–MS | ↓ | ↑ | ↓ | ↓ | ||||||||
Yu (2011)58 | Plasma | GC/TOF MS | ↑ | |||||||||||
Song (2012)51 | Serum | GC–MS | ↓ | ↓ | ||||||||||
Aa (2012)52 | Serum Tissue | GC/TOFMS | ↑ | ↑ | ↑ ↑ | |||||||||
Song (2012)56 | Tissue | GC–MS | ↓ | ↓ | ||||||||||
Mun (2004)70 | Tissue | 1H NMR | Decrease in lipids | |||||||||||
Tugnoli (2006)69 | Tissue | HR-MAS NMR | Increase in TAG | |||||||||||
Calabrese (2008)68 | Tissue | HR-MAS MRS | Increase in TAG | |||||||||||
Hirayama (2009)66 | Tissue | CE–MS | Increase in glyceraldehyde-3P | |||||||||||
Cai (2010)63 | Tissue | CE–MS | Increase in glyceraldehyde | |||||||||||
Jung (2014)39 | Urine Tissue | 1H NMR; HR-MAS NMR | Urine: increase in acetone Tissue: decrease in lipid I and lipid II | |||||||||||
Yang (2014)43 | Serum | LC-MS | Increase in PE, FFA, PC, SM, dihydrocholesterol Decrease in lyso-PC, lyso-PE, FFA, PC, choline, SM | |||||||||||
Kwon (2014)44 | Tissue | MALDI MS | Increase in SM Decrease in PC | |||||||||||
Wang (2016)33 | Tissue | 1H NMR | Decrease in lipids, VLDL, acetone, β-hydroxybutyrate | |||||||||||
Corona (2018)21 | Serum | LC-MS/MS | Increase in acylcarnitines derivatives (C2, C16, C18:1) Decrease in hydroxylated SM (SM(OH)22:1, SM(OH)22:2, SM(OH)24:1) and PC (PC ae 40:1, PC ae 42:2, PC ae 42:3) | |||||||||||
Lee (2019)19 | Plasma | nUHPLC-MS/MS | Increase in LPC18:2; LPE16:0 Decrease in PI; PE; LPE18:1; LPE18:0; LPC16:0; LPA18:2; PC | |||||||||||
EC | ||||||||||||||
Wu (2009)67 | Tissue | GC/MS | ↑ | ↑ | ||||||||||
Zhang (2012)54 | Serum | LC-MS and NMR | ↓ | ↓ | ↓ | ↑ | ||||||||
Zhang (2017)26 | Tissue | LC-MS | ↑ | ↑ | ||||||||||
Zhu (2017)29 | Serum Tissue | GC/TOF-MS | ↓ ↑ | ↑ | ||||||||||
Ayshamgul (2010)65 | Plasma | 1H NMR | Decrease in unsaturated lipid, VLDL and LDL, acetone | |||||||||||
Zhang (2011)60 | Serum | NMR | Increase in β-hydroxybutyrate | |||||||||||
Davis (2012)55 | Urine | 1H NMR | Decrease in acetone | |||||||||||
Hasim (2012)53 | Urine Plasma | 1H NMR | Decrease in unsaturated lipids, VLDL and LDL, acetone | |||||||||||
Zhang (2013)46 | Serum | 1H NMR; UHPLC | Increase in β-hydroxybutyrate Decrease in unsaturated lipids, VLDL and LDL | |||||||||||
Liu (2013)47 | Plasma | UPLC/TOF/MS | Increase in PI, PA, PC, PE, sphinganine-1-phosphate, PS (16:0/14:0) | |||||||||||
Wang (2013)48 | Tissue | 1H NMR | Increase in short-chain fatty acids, acetone Decrease in unsaturated lipids | |||||||||||
Mir (2015)38 | Serum | LC–MS | Increase in PC (20:4/0:0), PC (16:0/18:2), PC(18:1/18:1) Decrease in PC (18:2/0:0), PC (18:1/18:2), PC(O-18:1/18:2), PC(16:0/h18:2) | |||||||||||
Ma (2018)24 | Serum | 2D LC–MS | Decrease in fatty acids, PC, and FFA | |||||||||||
Tokunaga (2018)22 | Tissue | CE-TOFMS | Increase in betaine aldehyde Decrease in dihydroxyacetone |
EC, esophageal cancer; GC, gastric cancer; TAG, triacylglycerides; PE, phosphatidylethanolamine; FFA, free fatty acids; PC, phosphatidylcholine; SM, sphingomyelin; VLDL, very low-density lipoprotein; LDL, low-density lipoprotein; PI, phosphatidylinositol; PA, phosphatidic acid; PS, phosphatidylserine; 1H NMR, proton nuclear magnetic resonance; HR-MAS-NMR, high resolution-magic angle spinning-nuclear magnetic resonance spectroscopy; GC–MS, gas chromatography–mass spectrometry; CE–MS, capillary electrophoresis–mass spectrometry; HPLC–MS, high-performance liquid chromatography–mass spectrometry; LC–MS, liquid chromatography–mass spectrometry